🇺🇸 FDA
Patent

US 11685746

Heteroaryl compounds for treating Huntington's disease

granted A61PA61P25/00A61P25/14

Quick answer

US patent 11685746 (Heteroaryl compounds for treating Huntington's disease) held by PTC THERAPEUTICS, INC. expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PTC THERAPEUTICS, INC.
Grant date
Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61P, A61P25/00, A61P25/14, A61P25/28